Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. 02367.HK
stocks logo

02367.HK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast 02367.HK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02367.HK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 02367.HK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02367.HK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 38.220
sliders
Low
Averages
High
Current: 38.220
sliders
Low
Averages
High
CMB International
CMB International
Buy
downgrade
$53.89
2025-12-04
New
Reason
CMB International
CMB International
Price Target
$53.89
2025-12-04
New
downgrade
Buy
Reason
The analyst rating for GIANT BIOGENE (02367.HK) is maintained as a "Buy" despite short-term sales pressure during the Double 11 period. This decision is based on the company's strategic adjustments, including a focus on preserving price levels and consumer experience, as well as increasing the proportion of self-broadcast channels. These actions are seen as laying a foundation for long-term growth. However, the revenue growth rate for 2025 and 2026 has been revised downward due to the sales miss, leading to a target price adjustment to HKD53.89.
BofAS
BofAS
Outperform
to
Buy
downgrade
$70 -> $56
2025-12-04
New
Reason
BofAS
BofAS
Price Target
$70 -> $56
2025-12-04
New
downgrade
Outperform
to
Buy
Reason
The analyst rating for GIANT BIOGENE (02367.HK) is positive due to several key factors highlighted in the article. CICC views the company's plan to repurchase up to 104 million shares as a demonstration of management's confidence in the business. They believe that GIANT BIOGENE's strong R&D capabilities, brand recognition, and team cohesion will enable the company to enhance its operations by optimizing its product structure and adjusting operational strategies effectively. Additionally, the anticipated growth in its second curve medical beauty business contributes to CICC's optimistic outlook on the company's medium- to long-term growth potential, positioning it as a leader in recombinant collagen.
CICC
CICC
Outperform
to
Buy
downgrade
$70 -> $56
2025-12-03
New
Reason
CICC
CICC
Price Target
$70 -> $56
2025-12-03
New
downgrade
Outperform
to
Buy
Reason
The analyst rating from CICC for GIANT BIOGENE (02367.HK) is based on several positive factors. They view the company's plan to repurchase up to 104 million shares as a sign of management's confidence. Additionally, CICC highlights the company's solid research and development capabilities, strong brand recognition, and team cohesion. They believe that GIANT BIOGENE can enhance its operations through product structure optimization and strategic adjustments, particularly in its growing medical aesthetics business. CICC remains optimistic about the company's mid-to-long term growth potential as a leader in recombinant collagen, which supports their Outperform rating, despite a 20% cut in the target price to HKD56.
BofA Securities
BofA Securities
Buy
downgrade
2025-12-03
New
Reason
BofA Securities
BofA Securities
Price Target
2025-12-03
New
downgrade
Buy
Reason
The analyst rating from BofA Securities for GIANT BIOGENE is maintained at "Buy" despite lowering revenue and net profit forecasts for 2025-2027. The reason for this rating is the expectation that a newly approved injectable medical aesthetics product will serve as a new growth driver for the company in the upcoming year.
Citi
Buy
downgrade
2025-12-03
New
Reason
Citi
Price Target
2025-12-03
New
downgrade
Buy
Reason
The analyst rating for GIANT BIOGENE (02367.HK) is a "Buy" based on the expectation of a return to double-digit growth next year, driven by the continued growth of its live-streaming business and the launch of several major new products. However, the rating comes with a cautionary note, as the company's latest results guidance is at the lower end of market expectations, prompting Citi to cut its target price from HKD55.4 to HKD44.6.
CMBI
CMBI
Buy
downgrade
2025-10-24
Reason
CMBI
CMBI
Price Target
2025-10-24
downgrade
Buy
Reason
The analyst rating for GIANT BIOGENE remains a "Buy" despite a reduction in the target price from HKD71.3 to HKD58.35. This decision is based on the company's recent approval of its first injectable recombinant collagen product, which signifies a significant advancement in its product offerings and the completion of a comprehensive product matrix in the medical aesthetic sector. The ongoing commercialization of its injectable products further supports the positive outlook, leading the analyst to maintain the Buy rating.
See All Ratings

Valuation Metrics

The current forward P/E ratio for GIANT BIOGENE (02367.HK) is 13.88, compared to its 5-year average forward P/E of 21.55. For a more detailed relative valuation and DCF analysis to assess GIANT BIOGENE 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
21.55
Current PE
13.88
Overvalued PE
26.33
Undervalued PE
16.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
16.37
Current EV/EBITDA
9.46
Overvalued EV/EBITDA
20.66
Undervalued EV/EBITDA
12.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
8.32
Current PS
5.09
Overvalued PS
10.39
Undervalued PS
6.25
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

02367.HK News & Events

Events Timeline

Sign Up For More Events
no data image
No Data
Sign Up For More Events

News

[object Object]
Preview
4.0
10:04 AMaastocks
HSBC Research Lowers GIANT BIOGENE's Target Price to HKD46.4, Maintains Buy Rating

  • Earnings Guidance Update: GIANT BIOGENE updated its full-year results guidance and highlighted risks to 2025 earnings during a conference call, with HSBC Global Research reporting a significant earnings forecast reduction of 17-25% for 2025-27 due to pressures on the Comfy brand.

  • Target Price Adjustment: CMBI has maintained a "Buy" rating for GIANT BIOGENE but lowered its target price from HKD 69.3 to HKD 46.4 in light of the revised earnings expectations.

[object Object]
Preview
8.0
12-04aastocks
CICC Lowers GIANT BIOGENE's Target Price to HKD56, Remains Positive on Medium- to Long-Term Growth Prospects

  • Share Repurchase Announcement: GIANT BIOGENE plans to repurchase up to 104 million shares, representing 10% of its issued shares, and aims to enhance its product matrix, brand operations, and channel development by 2026.

  • Management Confidence: CICC views the buyback as a sign of management's confidence, highlighting the company's strong R&D capabilities and brand recognition, which are expected to drive operational improvements and growth in the medical beauty sector.

  • Target Price Adjustment: BofAS has reduced GIANT BIOGENE's target price by 20% to HKD56 while maintaining an Outperform rating, indicating a cautious outlook despite the company's potential.

  • Short Selling Data: The company has reported short selling of $87.94 million, with a ratio of 16.967%, reflecting market sentiment and trading activity surrounding its stock.

[object Object]
Preview
4.0
12-04aastocks
CMBI Lowers Price Target for GIANT BIOGENE (02367.HK) to $53.89, Maintains Buy Rating

  • Sales Pressure: GIANT BIOGENE faced sales pressure during the Double 11 period due to a sales miss from broadcasting, reflecting competitive industry pressures.

  • Strategic Adjustments: The company is adjusting its channel strategy while maintaining price levels and consumer experience, increasing the proportion of self-broadcast channels for long-term growth.

  • Analyst Ratings: Citi has lowered GIANT BIOGENE's target price to HKD44.6 while keeping a Buy rating, indicating confidence despite short-term challenges.

  • Revenue Forecast: CMB International revised the revenue growth rate for 2025 and 2026, projecting a decline of 3.5% followed by a rebound of 13.6%, with a new target price set at HKD53.89.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is GIANT BIOGENE (02367.HK) stock price today?

The current price of 02367.HK is 38.22 USD — it has increased 0.9 % in the last trading day.

arrow icon

What is GIANT BIOGENE (02367.HK)'s business?

arrow icon

What is the price predicton of 02367.HK Stock?

Wall Street analysts forecast 02367.HK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02367.HK is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is GIANT BIOGENE (02367.HK)'s revenue for the last quarter?

GIANT BIOGENE revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is GIANT BIOGENE (02367.HK)'s earnings per share (EPS) for the last quarter?

GIANT BIOGENE. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for GIANT BIOGENE (02367.HK)'s fundamentals?

The market is revising No Change the revenue expectations for 02367 for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by %.
arrow icon

How many employees does GIANT BIOGENE (02367.HK). have?

GIANT BIOGENE (02367.HK) has 0 emplpoyees as of December 05 2025.

arrow icon

What is GIANT BIOGENE (02367.HK) market cap?

Today 02367.HK has the market capitalization of 0.00 USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free